Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immatics ( (IMTX) ) has provided an update.
On November 12, 2025, Immatics N.V. announced updated data from its Phase 1a trials for IMA402 PRAME Bispecific and IMA401 MAGEA4/8 Bispecific, showcasing favorable tolerability and promising anti-tumor activity in heavily pre-treated patients with solid tumors. The trials demonstrated deep and durable responses, particularly in melanoma and ovarian carcinoma for IMA402, and head and neck cancer for IMA401. The company is advancing to Phase 1b dose expansion, exploring combination therapies, and potentially transitioning to Phase 2 trials, aiming to address significant unmet treatment needs and expand its pipeline’s impact on cancer care.
The most recent analyst rating on (IMTX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics faces significant financial challenges with declining revenues and profitability issues, which are the most impactful factors. Technical analysis shows mixed signals, with some potential for bullish momentum. However, valuation concerns due to negative earnings and lack of dividends further weigh down the score.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a clinical-stage biopharmaceutical company specializing in the development of TCR Bispecifics (TCER®) for precision targeting of cancer antigens. The company focuses on innovative therapies for solid tumors, particularly in melanoma, gynecologic cancers, and squamous non-small cell lung cancer (sqNSCLC).
Average Trading Volume: 902,028
Technical Sentiment Signal: Buy
Current Market Cap: $1.1B
Find detailed analytics on IMTX stock on TipRanks’ Stock Analysis page.